Free tool
FAERS Monitor: Curosurf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020744 or its brand name (Curosurf, Poractant Alfa). Reports on generic versions are filed under their own applications.
Reports
737
Serious
685
93% of reports
Hospitalization
100
Death reported
222
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neonatal hypoxia121
- off label use84
- pulmonary haemorrhage78
- bradycardia neonatal51
- ill-defined disorder50
- drug ineffective46
- product complaint40
- endotracheal intubation complication39
- pneumothorax37
- infantile apnoea30
- neonatal respiratory failure28
- pulmonary haemorrhage neonatal28
- product quality issue27
- product administration error26
- cyanosis neonatal24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 4 |
| 2006 | 16 |
| 2007 | 16 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 4 |
| 2012 | 13 |
| 2013 | 16 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 18 |
| 2017 | 31 |
| 2018 | 145 |
| 2019 | 68 |
| 2020 | 109 |
| 2021 | 41 |
| 2022 | 54 |
| 2023 | 42 |
| 2024 | 56 |
| 2025 | 16 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary haemorrhage neonatalSignal | 28 | 12497.8 | 8063.6 | 234,781 |
| neonatal hypoxiaSignal | 121 | 4895.9 | 4094.2 | 501,375 |
| endotracheal intubation complicationSignal | 39 | 2021.9 | 1473.2 | 71,697 |
| neonatal respiratory failureSignal | 28 | 1673.3 | 1151.0 | 42,643 |
| bradycardia neonatalSignal | 51 | 1207.0 | 920.7 | 57,817 |
| cyanosis neonatalSignal | 24 | 1111.2 | 743.8 | 24,567 |
| infantile apnoeaSignal | 30 | 1090.3 | 762.7 | 30,410 |
| pulmonary haemorrhageSignal | 78 | 287.4 | 232.7 | 21,762 |
| pneumothoraxSignal | 37 | 66.8 | 48.7 | 2,328 |
| product complaintSignal | 40 | 45.1 | 33.4 | 1,681 |
| product administration errorSignal | 26 | 36.8 | 25.2 | 869 |
| ill-defined disorderSignal | 50 | 23.5 | 18.0 | 1,057 |
| product quality issueSignal | 27 | 5.7 | 3.9 | 100 |
| off label useSignal | 84 | 2.7 | 2.2 | 95 |
| drug ineffective | 46 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.